In addition, the immunohistochemical analysis indicated that FGFC1 treatment remarkably reduced the expression of Ki-67 (0.56-fold), a marker for tumor cell proliferation [40], and significantly reduced the expression of p-p65, IL-6, and TNF-α (0.49-fold, 0.47-fold, and 0.50-fold, respectively), compared with the control group in tumor cells, which were consistent with the in vitro studies (Figure 5E,F). Here, IL6 is linked to neoplasm.